MX355102B - Procesos para hacer los inhibidores de la proteasa del hcv. - Google Patents
Procesos para hacer los inhibidores de la proteasa del hcv.Info
- Publication number
- MX355102B MX355102B MX2014008516A MX2014008516A MX355102B MX 355102 B MX355102 B MX 355102B MX 2014008516 A MX2014008516 A MX 2014008516A MX 2014008516 A MX2014008516 A MX 2014008516A MX 355102 B MX355102 B MX 355102B
- Authority
- MX
- Mexico
- Prior art keywords
- protease inhibitors
- processes
- hcv protease
- making hcv
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen procesos eficientes para hacer inhibidores de la proteasa del HCV. En una modalidad, el proceso usa nuevos derivados de idazolida de vinilo-ACCA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261585280P | 2012-01-11 | 2012-01-11 | |
PCT/US2013/021118 WO2013106631A1 (en) | 2012-01-11 | 2013-01-11 | Processes for making hcv protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008516A MX2014008516A (es) | 2014-08-21 |
MX355102B true MX355102B (es) | 2018-04-05 |
Family
ID=47599178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008516A MX355102B (es) | 2012-01-11 | 2013-01-11 | Procesos para hacer los inhibidores de la proteasa del hcv. |
Country Status (9)
Country | Link |
---|---|
US (1) | US9346785B2 (es) |
EP (1) | EP2802595B1 (es) |
JP (1) | JP6038179B2 (es) |
CN (2) | CN107964006A (es) |
CA (1) | CA2863002A1 (es) |
ES (1) | ES2563479T3 (es) |
HK (1) | HK1201277A1 (es) |
MX (1) | MX355102B (es) |
WO (1) | WO2013106631A1 (es) |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
US7173004B2 (en) | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
JP4704342B2 (ja) | 2003-09-22 | 2011-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対し活性な大環状ペプチド |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
WO2005090383A2 (en) | 2004-03-15 | 2005-09-29 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections |
US7323447B2 (en) * | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006138187A1 (en) | 2005-06-13 | 2006-12-28 | Yong-Qian Wu | Enhanced tissue penetration prodrugs |
TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
US20100018355A1 (en) | 2006-05-04 | 2010-01-28 | Crawford Ted C | Head cap for a wrench head, wrench and method utilizing the same |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US7728148B2 (en) | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
US20080033184A1 (en) | 2006-08-01 | 2008-02-07 | Alcon Manufacturing, Ltd. | Intermediates and methods for serotonergic agonist synthesis |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US20120220520A1 (en) | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
JP5352464B2 (ja) | 2006-10-27 | 2013-11-27 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
WO2008095058A1 (en) | 2007-02-01 | 2008-08-07 | Taigen Biotechnology Co. Ltd. | Hcv protease inhibitors |
US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
US20090111757A1 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
EP2250174B1 (en) | 2008-02-04 | 2013-08-28 | IDENIX Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
JP2011519364A (ja) | 2008-04-15 | 2011-07-07 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (zh) | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102177132B (zh) | 2008-10-10 | 2014-06-25 | 株式会社钟化 | 光学活性乙烯基环丙烷羧酸衍生物及光学活性乙烯基环丙烷氨基酸衍生物的制造方法 |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
TWI468160B (zh) | 2009-04-25 | 2015-01-11 | Hoffmann La Roche | 增進藥物動力學之方法 |
CA2774145C (en) | 2009-09-15 | 2015-10-27 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
-
2013
- 2013-01-11 JP JP2014552315A patent/JP6038179B2/ja not_active Expired - Fee Related
- 2013-01-11 CN CN201711334348.4A patent/CN107964006A/zh active Pending
- 2013-01-11 WO PCT/US2013/021118 patent/WO2013106631A1/en active Application Filing
- 2013-01-11 EP EP13700966.8A patent/EP2802595B1/en not_active Not-in-force
- 2013-01-11 CN CN201380005393.9A patent/CN104136453B/zh not_active Expired - Fee Related
- 2013-01-11 ES ES13700966.8T patent/ES2563479T3/es active Active
- 2013-01-11 MX MX2014008516A patent/MX355102B/es active IP Right Grant
- 2013-01-11 CA CA2863002A patent/CA2863002A1/en not_active Abandoned
- 2013-01-11 US US13/739,174 patent/US9346785B2/en not_active Expired - Fee Related
-
2015
- 2015-02-16 HK HK15101711.9A patent/HK1201277A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX2014008516A (es) | 2014-08-21 |
CA2863002A1 (en) | 2013-07-18 |
HK1201277A1 (zh) | 2015-08-28 |
WO2013106631A1 (en) | 2013-07-18 |
CN104136453B (zh) | 2018-01-12 |
US9346785B2 (en) | 2016-05-24 |
ES2563479T3 (es) | 2016-03-15 |
JP2015508413A (ja) | 2015-03-19 |
CN107964006A (zh) | 2018-04-27 |
JP6038179B2 (ja) | 2016-12-07 |
US20130178630A1 (en) | 2013-07-11 |
EP2802595B1 (en) | 2016-01-06 |
EP2802595A1 (en) | 2014-11-19 |
CN104136453A (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255870A1 (zh) | 作為二肽基肽酶 i 抑制劑的(2S)-N-[(1S)-1-氰基-2-苯基乙基]-1,4-氧雜氮雜環庚烷-2-甲醯胺 | |
MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
MY181069A (en) | Methods and processes for non-invasive assessment of genetic variations | |
UY34559A (es) | Inhibidores de bromodominios | |
EP3194369A4 (en) | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | |
IN2014DN08481A (es) | ||
PH12015500040B1 (en) | Supercritical hydrolysis of biomass | |
UA117565C2 (uk) | Модифікований олігонуклеотид | |
MX2015002487A (es) | Proceso para la preparacion de teneligliptina. | |
EA027567B9 (ru) | Способ приготовления стабильного при хранении напитка | |
MX369662B (es) | Granulos de harina de microalgas y proceso de preparacion de estos. | |
IN2014DN09798A (es) | ||
IN2014MU00455A (es) | ||
MX358132B (es) | Solucion de trombina y metodos de uso de esta. | |
IN2013MU01113A (es) | ||
IN2014DN10209A (es) | ||
IN2015DN03815A (es) | ||
IN2014DN11218A (es) | ||
MX2015009565A (es) | Proceso para elaborar derivados de magnolol. | |
MX355102B (es) | Procesos para hacer los inhibidores de la proteasa del hcv. | |
MX361888B (es) | Un procedimiento mejorado para producir zilpaterol. | |
GB2491544A (en) | Perpetum mobile | |
MX2017012348A (es) | Procesos e intermedios para preparar un inhibidor macrociclico de proteasa de vhc. | |
MX2015004411A (es) | Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). | |
UA68756U (uk) | Фторовмісні ізомерні бісдіоли, що містять азогрупи, як мономери для поліуретанів |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assignment |
Owner name: ABBVIE IRELAND UNLIMITED COMPANY |
|
FG | Grant or registration |